-
公开(公告)号：US20110269705A1
公开(公告)日：2011-11-03
申请号：US12668164
申请日：2009-12-04
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： A61K31/706 , A61K31/473 , C07D407/04 , C07D409/04 , C07D413/06 , A61K31/5377 , C07D413/14 , A61K31/553 , C07F9/60 , A61K31/675 , C07D401/14 , A61K31/496 , A61K31/397 , C07H19/048 , A61P3/10 , A61P35/00 , A61P9/00 , A61P25/18 , A61P25/00 , A61P25/24 , A61P13/12 , C07D215/233
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
摘要翻译： 本发明提供了抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的喹诺酮化合物，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的喹诺酮化合物由式（1）表示：其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示卤素等; R5表示氢等; R6表示氢等; 并且R 7表示氢等。
-
公开(公告)号：US20130005675A1
公开(公告)日：2013-01-03
申请号：US13616740
申请日：2012-09-14
申请人： Kenji OTSUBO , Takahito YAMAUCHI , Yuji OCHI
发明人： Kenji OTSUBO , Takahito YAMAUCHI , Yuji OCHI
IPC分类号： A61K31/473 , C07D405/04 , C07D409/04 , C07D221/16 , C07D413/06 , A61K31/5377 , C07D401/06 , C07D413/14 , A61K31/553 , C07F9/576 , A61K31/685 , A61K31/675 , A61K31/496 , C07D491/052 , C07F9/6561 , C07D491/048 , C07D471/04 , C07D215/233 , A61K31/47 , A61K31/551 , C07H19/04 , A61K31/706 , A61P25/00 , A61P9/10 , A61P9/04 , A61P9/00 , A61P13/12 , A61P11/00 , A61P25/24 , A61P25/18 , A61P3/10 , A61P25/06 , A61P27/16 , A61P27/02 , A61P25/16 , A61P25/28 , C07D221/10
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
摘要翻译： 本发明提供了抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的喹诺酮化合物，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的喹诺酮化合物由式（1）表示：其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示卤素等; R5表示氢等; R6表示氢等; 并且R 7表示氢等。
-
公开(公告)号：US08304546B2
公开(公告)日：2012-11-06
申请号：US12668164
申请日：2009-12-04
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： C07D215/38
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
摘要翻译： 本发明提供了抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的喹诺酮化合物，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的喹诺酮化合物由式（1）表示：其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示卤素等; R5表示氢等; R6表示氢等; 并且R 7表示氢等。
-
公开(公告)号：US20100261705A1
公开(公告)日：2010-10-14
申请号：US12611921
申请日：2009-11-03
申请人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Ohta Kazuhide , Masaaki Takano , Takumi Sumida
发明人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Ohta Kazuhide , Masaaki Takano , Takumi Sumida
IPC分类号： A61K31/4709 , C07D417/10 , C07D417/14 , A61K31/5377 , A61K31/496 , A61K31/506 , A61K31/473 , A61K31/498 , A61K31/55 , A61P1/00 , A61P11/00 , A61P27/02 , A61P35/00 , A61P17/02
CPC分类号： C07D471/08 , C07D417/04 , C07D417/06 , C07D417/14 , C07D487/04 , C07D495/04
摘要： The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R1 is a hydrogen atom, etc; R2 is a hydrogen atom, etc; and R3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.
摘要翻译： 本发明提供由通式（1）表示的喹诺酮化合物或其盐，其中A为直接键，低级亚烷基或低级亚烷基; X是氧原子或硫原子; R4和R5各自表示氢原子; 喹诺酮骨架的3和4位之间的键是单键或双键; R1是氢原子等; R2是氢原子等; R3是氢原子等。本发明的喹诺酮化合物或其盐诱导TFF的产生，因此可用于治疗和/或预防诸如消化道疾病，口腔疾病，上呼吸道疾病 疾病，呼吸道疾病，眼睛疾病，癌症和伤口。
-
公开(公告)号：US20070179173A1
公开(公告)日：2007-08-02
申请号：US10582014
申请日：2005-09-26
申请人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Kazuhide Ohta , Masaaki Takano , Takumi Sumida
发明人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Kazuhide Ohta , Masaaki Takano , Takumi Sumida
IPC分类号： A61K31/473 , A61K31/4709 , C07D417/14
CPC分类号： C07D471/08 , C07D417/04 , C07D417/06 , C07D417/14 , C07D487/04 , C07D495/04
摘要： The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R1 is a hydrogen atom, etc; R2 is a hydrogen atom, etc; and R3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.
摘要翻译： 本发明提供由通式（1）表示的喹诺酮化合物或其盐，其中A为直接键，低级亚烷基或低级亚烷基; X是氧原子或硫原子; R 4和R 5各自表示氢原子; 喹诺酮骨架的3和4位之间的键是单键或双键; R 1是氢原子等; R 2是氢原子等; 和R 3是氢原子等。本发明的喹诺酮化合物或其盐诱导TFF的产生，因此可用于治疗和/或预防诸如消化道 疾病，口腔疾病，上呼吸道疾病，呼吸道疾病，眼睛疾病，癌症和伤口。
-
公开(公告)号：US06140330A
公开(公告)日：2000-10-31
申请号：US43642
申请日：1998-03-24
申请人： Toyoki Mori , Michiaki Tominaga , Fujio Tabusa , Kazuyoshi Nagami , Kaoru Abe , Kenji Nakaya , Isao Takemura , Tomoichi Shinohara , Yoshihisa Tanada , Takahito Yamauchi
发明人： Toyoki Mori , Michiaki Tominaga , Fujio Tabusa , Kazuyoshi Nagami , Kaoru Abe , Kenji Nakaya , Isao Takemura , Tomoichi Shinohara , Yoshihisa Tanada , Takahito Yamauchi
IPC分类号： C07D277/46 , C07D277/82 , C07D317/64 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , A61K31/495 , A61K31/445 , C07D413/02
CPC分类号： C07D417/12 , C07D277/46 , C07D277/82 , C07D317/64 , C07D417/14 , C07D471/04 , C07D487/04
摘要： A thiazole compound of the formula: ##STR1## wherein T is lower alkylene; u is 0 or 1; R.sup.1 and R.sup.2 are the same or different and are each H, or lower alkyl, etc.; R.sup.3 is ##STR2## R.sup.4 is H or lower alkanoyloxy-lower alkyl, which shows inhibitory activity on protein kinase C (PKC, Ca.sup.2+ /phospholipid-depending serine/threonine protein phosphatase), and are useful as a protein kinase C inhibitor.
摘要翻译： PCT No.PCT / JP97 / 02609 Sec。 371日期：1998年3月24日 102（e）1998年3月24日PCT PCT 1997年7月29日PCT公布。 第WO98 / 04536号公报 日期：1998年2月5日A下式的噻唑化合物：其中T是低级亚烷基; 你是0或1; R1和R2相同或不同，各自为H或低级烷基等; R3是R4是H或低级烷酰氧基 - 低级烷基，它对蛋白激酶C（PKC，Ca2 + /磷脂依赖性丝氨酸/苏氨酸蛋白磷酸酶）具有抑制活性，可用作蛋白激酶C抑制剂。
-
公开(公告)号：US07777038B2
公开(公告)日：2010-08-17
申请号：US10582014
申请日：2005-09-26
申请人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Kazuhide Ohta , Masaaki Takano , Takumi Sumida
发明人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Kazuhide Ohta , Masaaki Takano , Takumi Sumida
IPC分类号： C07D215/38
CPC分类号： C07D471/08 , C07D417/04 , C07D417/06 , C07D417/14 , C07D487/04 , C07D495/04
摘要： The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R1 is a hydrogen atom, etc; R2 is a hydrogen atom, etc; and R3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.
摘要翻译： 本发明提供由通式（1）表示的喹诺酮化合物或其盐，其中A为直接键，低级亚烷基或低级亚烷基; X是氧原子或硫原子; R4和R5各自表示氢原子; 喹诺酮骨架的3和4位之间的键是单键或双键; R1是氢原子等; R2是氢原子等; R3是氢原子等。本发明的喹诺酮化合物或其盐诱导TFF的产生，因此可用于治疗和/或预防诸如消化道疾病，口腔疾病，上呼吸道疾病 疾病，呼吸道疾病，眼睛疾病，癌症和伤口。
-
公开(公告)号：USRE45108E1
公开(公告)日：2014-09-02
申请号：US14038862
申请日：2013-09-27
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： C07D221/06 , C07D215/38 , C07D215/233 , C07D215/18
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
摘要翻译： 本发明提供了抑制帕金森病慢性进展或保护多巴胺神经元免受疾病病因的喹诺酮化合物，从而抑制神经功能障碍的进展，从而延长使用L-多巴的时间，同时也改善神经元功能 ; 本发明的喹诺酮化合物由式（1）表示：其中：R1表示氢等; R2表示氢等; R3表示取代或未取代的苯基等; R4表示卤素等; R5表示氢等; R6表示氢等; 并且R 7表示氢等。
-
公开(公告)号：US08592593B2
公开(公告)日：2013-11-26
申请号：US13616740
申请日：2012-09-14
申请人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
发明人： Kenji Otsubo , Takahito Yamauchi , Yuji Ochi
IPC分类号： C07D215/38
CPC分类号： C07D221/06 , C07D215/18 , C07D215/22 , C07D215/233 , C07D215/26 , C07D215/28 , C07D215/40 , C07D215/48 , C07D221/10 , C07D221/16 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D413/14 , C07D471/04 , C07D491/04 , C07F9/60 , C07F9/65583 , C07F9/6561 , C07H19/04
摘要： The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.
-
公开(公告)号：US08362252B2
公开(公告)日：2013-01-29
申请号：US12611921
申请日：2009-11-03
申请人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Kazuhide Ohta , Masaaki Takano , Takumi Sumida
发明人： Takeshi Kuroda , Takahito Yamauchi , Tomoichi Shinohara , Kunio Oshima , Chiharu Kitajima , Hitoshi Nagao , Tae Fukushima , Takahiro Tomoyasu , Hironobu Ishiyama , Kazuhide Ohta , Masaaki Takano , Takumi Sumida
IPC分类号： C07D215/38
CPC分类号： C07D471/08 , C07D417/04 , C07D417/06 , C07D417/14 , C07D487/04 , C07D495/04
摘要： The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R1 is a hydrogen atom, etc; R2 is a hydrogen atom, etc; and R3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.
摘要翻译： 本发明提供由通式（1）表示的喹诺酮化合物或其盐，其中A为直接键，低级亚烷基或低级亚烷基; X是氧原子或硫原子; R4和R5各自表示氢原子; 喹诺酮骨架的3和4位之间的键是单键或双键; R1是氢原子等; R2是氢原子等; R3是氢原子等。本发明的喹诺酮化合物或其盐诱导TFF的产生，因此可用于治疗和/或预防诸如消化道疾病，口腔疾病，上呼吸道疾病 疾病，呼吸道疾病，眼睛疾病，癌症和伤口。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.036 秒)
